Stronger statin doses to bind Kidney Injury

A new study has found that statins potentially powerful high-risk hospitalized for acute kidney injury compared with statins less powerful and even risk will continue for two years.

Lead researcher Colin Dormuth, from the University of British Columbia, Vancouver, Canada, and colleagues, write about their findings in a paper BMJ published online on March 19.

Statins are cholesterol-lowering drug class as a way to reduce the risk of cardiovascular disease, with higher doses given to those at high risk.

Largely as a result of clinical trials showed improved cardiovascular outcomes, following the trend of increasing the potential of statins, both with larger doses, such as simvastatin or atorvastatin 40-80 mg, or a stronger dose, rosuvastatin.

But researchers are beginning to show that an increase in adverse causing kidney problems, and because statins are so widely used, because it is the result of a side effect.

Because clinical trials did not involve a lot of people, so that these side effects may not be sufficiently general to be notified to the public and only in postmarketing monitoring, and analysis of a large group of patients, so that they began to arise the problem.